Drug intelligence / Profile preview

zastumotide + AS02B

Development stage: Unknown
Lead developer: GSK
Modality: Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**Zastumotide + AS02B** is an investigational therapeutic cancer vaccine formulation containing recombinant MAGE-A3 antigen protein and the AS02B immunological adjuvant system. MAGE-A3 is a cancer-testis antigen expressed by a subset of melanomas, enabling antigen-directed immune recognition of tumor cells. AS02B enhances vaccine-induced cellular and humoral immunity to the recombinant antigen. The formulation was evaluated by the European Organisation for Research and Treatment of Cancer in the randomized open-label phase II EORTC 16032-18031 study in patients with MAGE-A3-positive unresectable stage III or stage IV M1a cutaneous melanoma. Clinical and immunologic activity was inferior to the corresponding MAGE-A3 plus AS15 regimen, and AS15 was selected for later development.

Other names: astuprotimut-R + AS02BD1/3-MAGE-3-His fusion protein + SB-AS02BMAGE-A3 protein + AS02BrecMAGE-A3 + AS02Brecombinant MAGE-A3 protein + AS02B

Targets

MAGEA3 (Melanoma-associated antigen 3)

Beyond the preview

Go deeper on zastumotide + AS02B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on zastumotide + AS02B.

Explore the full profile